Together, these studies indicate that FAK is a key signaling mediator downstream of various integrins under differential flow conditions in ECs during the initiation and progression of atherosclerotic lesions, making it a potential candidate for the treatment of atherosclerosis. The gene discussed is PTK2; the disease is atherosclerosis.